LSD1-IN-13 hydrochloride
Modify Date: 2024-01-17 18:03:02
LSD1-IN-13 hydrochloride structure
|
Common Name | LSD1-IN-13 hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 2170347-90-5 | Molecular Weight | 448.02 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H30ClN3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LSD1-IN-13 hydrochlorideLSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines[1]. |
| Name | LSD1-IN-13 hydrochloride |
|---|
| Description | LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent LSD1 inhibitor, with an IC50 of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC50 of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 24.43 ± 1.08 nM (LSD1), 5.00 ± 0.28 μM (LSD2), >100 μM (MAO-A), >100 μM (MAO-B)[1] |
| In Vitro | LSD1-IN-13 hydrochloride (compound 7e) shows good selectivity over LSD2 (205-fold) and MAOs (>4000-fold)[1]. LSD1-IN-13 hydrochloride shows potent and selective antiproliferative activity in MV-4-11, with an IC50 of 1.36 μM[1]. |
| In Vivo | LSD1-IN-13 hydrochloride (compound 7e) (MV-4-11 xenograft mice, 0-20 mg/kg, Orally, daily for 15 days) suppresses tumor growth significantly in a dose-dependent manner[1]. |
| References |
| Molecular Formula | C23H30ClN3O2S |
|---|---|
| Molecular Weight | 448.02 |